Flagship Pioneering

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Cellarity Inc is a therapeutics company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines through the analysis of cellular behaviors. Established in 2017, the company employs advanced genomic technologies, data science, and artificial intelligence to create a comprehensive platform that digitizes molecular information within cells. This approach allows Cellarity to investigate how cells function in both health and disease, aiming to address the complexities of various medical conditions. By leveraging single-cell technologies and machine learning, the company seeks to enhance the success rate and efficiency of drug discovery, ultimately designing therapies that effectively target the intricate dynamics of cellular behavior.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

CIBO Technologies, Inc. is a company that specializes in developing software products to model and simulate agricultural ecosystems, aimed at enhancing sustainable practices in agriculture. Its key offerings include Continuum DB, a distributed database for spatio-temporal modeling; BarnCAT, a computational agronomy toolkit; WhetherRain, an integrated weather simulation tool; and DirtPatch, a platform for environmental reconstruction. Additionally, CIBO provides TerraFarm for planetary-scale simulations and the Land Intelligence platform, which generates insights on agricultural parcels while offering access to publicly available data for various stakeholders in the agriculture sector. The company's solutions are designed to support a wide range of crops and serve multiple industries, including farm services, agribusiness, and sustainability. Founded in 2014 and based in Cambridge, Massachusetts, with additional offices in Saint Louis, East Lansing, and Minneapolis, CIBO aims to advance food system resilience and improve grower outcomes in the face of climate change.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Invaio Sciences is a multi-platform technology company focused on solving agriculture, nutrition, and environmental challenges by applying advanced science to understand the physiology of insects and the interdependent natural systems that shape crop health. Headquartered in Cambridge, Massachusetts, with additional locations in Durham, North Carolina; Basel, Switzerland; and São Paulo, Brazil, the company develops technologies to reduce pesticide use, conserve water, and improve crop health, while pursuing breakthrough solutions across agriculture, human health, animal nutrition, and animal health.

Repertoire Immune Medicines, Inc. is a clinical stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company focuses on harnessing the power of T cells to develop innovative treatments for cancer, autoimmune diseases, and infectious diseases. By utilizing autologous T cells that are primed against specific cancer antigens and tethered to IL-15, Repertoire Immune Medicines aims to unlock and direct the human immune system to effectively prevent and treat various conditions. The company also specializes in characterizing T cell receptor (TCR)-antigen pairs and rationally designing targeted immune medicines, thereby enhancing the potential for effective therapies in serious health challenges.

Omega Therapeutics, Inc. is a development-stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in developing genomic medicines aimed at curing diseases through precision tuning of the human genome. It utilizes its proprietary epigenomic programming platform to engineer a new class of programmable epigenetic medicines known as Omega Epigenomic Controllers. These controllers are designed to selectively regulate genomic activity, allowing for the downregulation or upregulation of genes to achieve therapeutic effects. Omega Therapeutics seeks to transform human medicine by harnessing the natural capacity of the genome to treat and cure various diseases.

Cellarity Inc is a therapeutics company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines through the analysis of cellular behaviors. Established in 2017, the company employs advanced genomic technologies, data science, and artificial intelligence to create a comprehensive platform that digitizes molecular information within cells. This approach allows Cellarity to investigate how cells function in both health and disease, aiming to address the complexities of various medical conditions. By leveraging single-cell technologies and machine learning, the company seeks to enhance the success rate and efficiency of drug discovery, ultimately designing therapies that effectively target the intricate dynamics of cellular behavior.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Omega Therapeutics, Inc. is a development-stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in developing genomic medicines aimed at curing diseases through precision tuning of the human genome. It utilizes its proprietary epigenomic programming platform to engineer a new class of programmable epigenetic medicines known as Omega Epigenomic Controllers. These controllers are designed to selectively regulate genomic activity, allowing for the downregulation or upregulation of genes to achieve therapeutic effects. Omega Therapeutics seeks to transform human medicine by harnessing the natural capacity of the genome to treat and cure various diseases.

Founded in 2018, Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. The company aims to reprogram cells in the body or replace damaged ones to treat a broad range of diseases, with a pipeline including SC291, SC262, SC255, UP421, and other candidates across therapeutic areas like oncology, diabetes, autoimmune disorders, and CNS.

Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing functional cures for patients with chronic diseases. Founded in 2015, the company aims to create immune-protected, engineered human cells that restore normal physiological functions without the risk of fibrosis or immune rejection. Its lead product candidate, SIG-001, is currently in Phase I/II clinical trials for preventing bleeding episodes in patients with moderate to severe Hemophilia A. Additionally, Sigilon is advancing other candidates, including SIG-005, which targets non-neurological manifestations of mucopolysaccharidosis type 1, and SIG-002, designed to replace islet cells for treating type 1 diabetes. The company's innovative Shielded Living Therapeutics platform leverages advances in cell engineering and proprietary biocompatible materials to offer stable and durable therapeutic solutions for a variety of chronic conditions.

Ohana Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming reproductive health through innovative molecular techniques. Founded in 2015 and originally known as VL34, Inc., the company specializes in developing reproductive medicines aimed at enhancing sperm quality and function. Ohana Biosciences addresses infertility, mitigates inherited diseases, and aims to produce a long-lasting, reversible, and non-hormonal male contraceptive. By concentrating on sperm biology rather than egg biology, the company seeks to improve fertility rates, provide non-hormonal contraception options, and reduce pregnancy-related complications.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Invaio Sciences is a multi-platform technology company focused on solving agriculture, nutrition, and environmental challenges by applying advanced science to understand the physiology of insects and the interdependent natural systems that shape crop health. Headquartered in Cambridge, Massachusetts, with additional locations in Durham, North Carolina; Basel, Switzerland; and São Paulo, Brazil, the company develops technologies to reduce pesticide use, conserve water, and improve crop health, while pursuing breakthrough solutions across agriculture, human health, animal nutrition, and animal health.

Cellarity Inc is a therapeutics company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines through the analysis of cellular behaviors. Established in 2017, the company employs advanced genomic technologies, data science, and artificial intelligence to create a comprehensive platform that digitizes molecular information within cells. This approach allows Cellarity to investigate how cells function in both health and disease, aiming to address the complexities of various medical conditions. By leveraging single-cell technologies and machine learning, the company seeks to enhance the success rate and efficiency of drug discovery, ultimately designing therapies that effectively target the intricate dynamics of cellular behavior.

Cygnal Therapeutics, established in 2016 in Cambridge, Massachusetts, specializes in developing drugs that target and manipulate exoneural biology for treating cancer, immunological diseases, and regenerative processes. The company leverages a state-of-the-art neurotechnology platform to uncover novel aspects of neural function, enabling innovative therapeutic approaches. Cygnal was founded by Flagship Pioneering through its VentureLabs innovation foundry.

Founded in 2018, Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. The company aims to reprogram cells in the body or replace damaged ones to treat a broad range of diseases, with a pipeline including SC291, SC262, SC255, UP421, and other candidates across therapeutic areas like oncology, diabetes, autoimmune disorders, and CNS.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

Rubius Therapeutics, Inc. is a biotechnology company focused on developing red cell therapeutics (RCTs) aimed at treating patients with severe diseases, including cancer, enzyme deficiencies, and autoimmune disorders. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. By creating a new class of medicines, Rubius Therapeutics seeks to address significant unmet medical needs through innovative approaches in the field of biotechnology.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Repertoire Immune Medicines, Inc. is a clinical stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company focuses on harnessing the power of T cells to develop innovative treatments for cancer, autoimmune diseases, and infectious diseases. By utilizing autologous T cells that are primed against specific cancer antigens and tethered to IL-15, Repertoire Immune Medicines aims to unlock and direct the human immune system to effectively prevent and treat various conditions. The company also specializes in characterizing T cell receptor (TCR)-antigen pairs and rationally designing targeted immune medicines, thereby enhancing the potential for effective therapies in serious health challenges.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

Omega Therapeutics, Inc. is a development-stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in developing genomic medicines aimed at curing diseases through precision tuning of the human genome. It utilizes its proprietary epigenomic programming platform to engineer a new class of programmable epigenetic medicines known as Omega Epigenomic Controllers. These controllers are designed to selectively regulate genomic activity, allowing for the downregulation or upregulation of genes to achieve therapeutic effects. Omega Therapeutics seeks to transform human medicine by harnessing the natural capacity of the genome to treat and cure various diseases.

Evelo Biosciences, Inc., established in 2015, is a biotechnology company based in Cambridge, Massachusetts. It specializes in the discovery and development of a novel class of medicines known as monoclonal microbials, which are orally delivered and designed to modulate systemic immunology and biology by interacting with human cells in the gut. Evelo's pipeline includes EDP1815, currently in a Phase 1b clinical trial for psoriasis and atopic dermatitis, and EDP1503, in a Phase 1/2 study for various cancer types, including colorectal, triple-negative breast, and melanoma. The company aims to apply this innovative approach across a broad range of diseases, including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory conditions, and cancer.

Rubius Therapeutics, Inc. is a biotechnology company focused on developing red cell therapeutics (RCTs) aimed at treating patients with severe diseases, including cancer, enzyme deficiencies, and autoimmune disorders. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. By creating a new class of medicines, Rubius Therapeutics seeks to address significant unmet medical needs through innovative approaches in the field of biotechnology.

CIBO Technologies, Inc. is a company that specializes in developing software products to model and simulate agricultural ecosystems, aimed at enhancing sustainable practices in agriculture. Its key offerings include Continuum DB, a distributed database for spatio-temporal modeling; BarnCAT, a computational agronomy toolkit; WhetherRain, an integrated weather simulation tool; and DirtPatch, a platform for environmental reconstruction. Additionally, CIBO provides TerraFarm for planetary-scale simulations and the Land Intelligence platform, which generates insights on agricultural parcels while offering access to publicly available data for various stakeholders in the agriculture sector. The company's solutions are designed to support a wide range of crops and serve multiple industries, including farm services, agribusiness, and sustainability. Founded in 2014 and based in Cambridge, Massachusetts, with additional offices in Saint Louis, East Lansing, and Minneapolis, CIBO aims to advance food system resilience and improve grower outcomes in the face of climate change.

Oasys Water, Inc. is a Boston-based company that specializes in forward osmosis technology aimed at addressing the global water crisis. Founded in 2008, the company has developed Engineered Osmosis, a proprietary platform that enhances the efficiency of desalination processes, making the treatment of saltwater more economical. Oasys Water's integrated systems focus on high recovery desalination, brine management, and zero liquid discharge solutions. By utilizing advanced resource recovery techniques, the company significantly lowers the cost of producing clean water and energy, enabling industries to optimize resource use while minimizing environmental impact. Oasys Water also maintains an office in Dubai to support its international operations.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Rubius Therapeutics, Inc. is a biotechnology company focused on developing red cell therapeutics (RCTs) aimed at treating patients with severe diseases, including cancer, enzyme deficiencies, and autoimmune disorders. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. By creating a new class of medicines, Rubius Therapeutics seeks to address significant unmet medical needs through innovative approaches in the field of biotechnology.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Evelo Biosciences, Inc., established in 2015, is a biotechnology company based in Cambridge, Massachusetts. It specializes in the discovery and development of a novel class of medicines known as monoclonal microbials, which are orally delivered and designed to modulate systemic immunology and biology by interacting with human cells in the gut. Evelo's pipeline includes EDP1815, currently in a Phase 1b clinical trial for psoriasis and atopic dermatitis, and EDP1503, in a Phase 1/2 study for various cancer types, including colorectal, triple-negative breast, and melanoma. The company aims to apply this innovative approach across a broad range of diseases, including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory conditions, and cancer.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

Joule Unlimited, Inc., established in 2007, specializes in developing technology to produce low-carbon transportation fuels. The company's core process involves using solar energy to convert waste CO2 into renewable fuels, such as ethanol and hydrocarbons suitable for diesel, jet fuel, and gasoline. Joule Unlimited serves a global customer base, with operations in the United States, Europe, Australia, Mexico, and China. Notably, it has a strategic partnership with Audi. The company's products include Sunflow-E, a solar ethanol, and Sunflow-D, a solar diesel. Joule Unlimited is headquartered in Cambridge, Massachusetts, with additional offices in Los Angeles, California, and The Hague, the Netherlands, and production facilities in Hobbs, New Mexico.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, specializing in the development of microbiome therapeutics aimed at restoring health by correcting dysbiotic microbiomes. The company's lead product candidate, SER-109, is currently in Phase III clinical trials for the prevention of recurrent Clostridium difficile infection (CDI). In addition to SER-109, Seres is advancing several other therapeutic candidates: SER-287, which is in a Phase IIb study for ulcerative colitis; SER-401, a microbiome therapeutic in a Phase Ib study for use with checkpoint inhibitors in metastatic melanoma; SER-301 for inflammatory bowel disease; SER-262 for initial CDI recurrence; and SER-155 to address dysbiosis post-allogeneic hematopoietic stem cell transplants. Seres Therapeutics collaborates with notable institutions such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and has partnered with AstraZeneca to enhance its research and development efforts. Founded in 2010, Seres Therapeutics was previously known as Seres Health, Inc. until its name change in May 2015.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

Black Duck secures and manages open source software worldwide, eliminating open source security vulnerabilities and license compliance pain. With the rapid, widespread adoption of open-source software, Black Duck is a key component of Synopsys’ Software Integrity Platform, the most comprehensive solution for integrating security into the SDLC and software supply chain. Black Duck was established in 2002 and is based in Burlington, Massachusetts, United States.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, specializing in the development of microbiome therapeutics aimed at restoring health by correcting dysbiotic microbiomes. The company's lead product candidate, SER-109, is currently in Phase III clinical trials for the prevention of recurrent Clostridium difficile infection (CDI). In addition to SER-109, Seres is advancing several other therapeutic candidates: SER-287, which is in a Phase IIb study for ulcerative colitis; SER-401, a microbiome therapeutic in a Phase Ib study for use with checkpoint inhibitors in metastatic melanoma; SER-301 for inflammatory bowel disease; SER-262 for initial CDI recurrence; and SER-155 to address dysbiosis post-allogeneic hematopoietic stem cell transplants. Seres Therapeutics collaborates with notable institutions such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and has partnered with AstraZeneca to enhance its research and development efforts. Founded in 2010, Seres Therapeutics was previously known as Seres Health, Inc. until its name change in May 2015.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Avedro, Inc. is a commercial-stage ophthalmic pharmaceutical and medical device company headquartered in Waltham, Massachusetts. The company specializes in developing and commercializing innovative products for treating corneal disorders, primarily focusing on corneal ectatic conditions and refractive issues. Avedro's proprietary Corneal Remodeling Platform includes the KXL and Mosaic systems, which utilize ultraviolet A (UVA) light in conjunction with riboflavin drug formulations for corneal cross-linking. This technology is aimed at strengthening and reshaping the cornea through minimally invasive and non-invasive outpatient procedures. Avedro has also introduced the Keraflex refractive correction procedure, a non-invasive technique for flattening the cornea without tissue removal. While Avedro primarily serves ophthalmologists, hospitals, and ambulatory surgery centers in the United States, it also markets its products internationally through medical device distributors. The company, originally named ThermalVision, Inc., was incorporated in 2002 and rebranded as Avedro in 2005. As of November 2019, Avedro operates as a subsidiary of Glaukos Corporation.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, specializing in the development of microbiome therapeutics aimed at restoring health by correcting dysbiotic microbiomes. The company's lead product candidate, SER-109, is currently in Phase III clinical trials for the prevention of recurrent Clostridium difficile infection (CDI). In addition to SER-109, Seres is advancing several other therapeutic candidates: SER-287, which is in a Phase IIb study for ulcerative colitis; SER-401, a microbiome therapeutic in a Phase Ib study for use with checkpoint inhibitors in metastatic melanoma; SER-301 for inflammatory bowel disease; SER-262 for initial CDI recurrence; and SER-155 to address dysbiosis post-allogeneic hematopoietic stem cell transplants. Seres Therapeutics collaborates with notable institutions such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and has partnered with AstraZeneca to enhance its research and development efforts. Founded in 2010, Seres Therapeutics was previously known as Seres Health, Inc. until its name change in May 2015.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

WikiCell Designs Inc., a Cambridge, Mass. and Paris, France-based company developing edible forms of food and beverage packaging.

Sesen Bio, Inc. is a late-stage clinical company based in Cambridge, Massachusetts, that focuses on the design, development, and commercialization of targeted fusion protein therapeutics for cancer treatment. The company's lead product candidate, Vicinium, is a locally-administered therapy currently in phase 3 clinical trials aimed at treating high-risk non-muscle invasive bladder cancer. Additionally, Sesen Bio is developing VB6-845d, a systemically-administered product for various EpCAM-positive solid tumors. The company is also exploring combination therapies, including Vicinium with Durvalumab for high-risk non-muscle invasive bladder cancer and another combination for squamous cell carcinoma of the head and neck. Sesen Bio has partnered with Leiden University Medical Center to co-develop an imaging agent. Established in 2008 and previously known as Eleven Biotherapeutics, Sesen Bio has developed a proprietary platform that combines antibody fragments with cytotoxic proteins to create innovative therapies.

Founded in 2005 through the merger of leading optical technology companies from Cambridge, Massachusetts, and Cambridge, UK, Polatis specializes in developing and providing optical switching solutions for modern fiber-based networks.

Joule Unlimited, Inc., established in 2007, specializes in developing technology to produce low-carbon transportation fuels. The company's core process involves using solar energy to convert waste CO2 into renewable fuels, such as ethanol and hydrocarbons suitable for diesel, jet fuel, and gasoline. Joule Unlimited serves a global customer base, with operations in the United States, Europe, Australia, Mexico, and China. Notably, it has a strategic partnership with Audi. The company's products include Sunflow-E, a solar ethanol, and Sunflow-D, a solar diesel. Joule Unlimited is headquartered in Cambridge, Massachusetts, with additional offices in Los Angeles, California, and The Hague, the Netherlands, and production facilities in Hobbs, New Mexico.

Agios Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapies in the field of cellular metabolism. It discovers and develops medicines for various indications, including hematologic malignancies, solid tumors, and rare genetic diseases.

Black Duck secures and manages open source software worldwide, eliminating open source security vulnerabilities and license compliance pain. With the rapid, widespread adoption of open-source software, Black Duck is a key component of Synopsys’ Software Integrity Platform, the most comprehensive solution for integrating security into the SDLC and software supply chain. Black Duck was established in 2002 and is based in Burlington, Massachusetts, United States.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

Everyday Solutions, Inc. specializes in GPS-based vehicle tracking solutions tailored for the student transportation market in the United States and Canada. The company delivers real-time tracking services that ensure route compliance, driver safety, student attendance monitoring, automatic notifications for parents, and comprehensive management reporting. Founded in 2000 as Everyday Wireless, Inc., it rebranded to Everyday Solutions, Inc. in July 2008. Headquartered in Concord, Massachusetts, the company has established strategic partnerships with various organizations, enhancing its service offerings within the pupil transportation sector.

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Joule Unlimited, Inc., established in 2007, specializes in developing technology to produce low-carbon transportation fuels. The company's core process involves using solar energy to convert waste CO2 into renewable fuels, such as ethanol and hydrocarbons suitable for diesel, jet fuel, and gasoline. Joule Unlimited serves a global customer base, with operations in the United States, Europe, Australia, Mexico, and China. Notably, it has a strategic partnership with Audi. The company's products include Sunflow-E, a solar ethanol, and Sunflow-D, a solar diesel. Joule Unlimited is headquartered in Cambridge, Massachusetts, with additional offices in Los Angeles, California, and The Hague, the Netherlands, and production facilities in Hobbs, New Mexico.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Sesen Bio, Inc. is a late-stage clinical company based in Cambridge, Massachusetts, that focuses on the design, development, and commercialization of targeted fusion protein therapeutics for cancer treatment. The company's lead product candidate, Vicinium, is a locally-administered therapy currently in phase 3 clinical trials aimed at treating high-risk non-muscle invasive bladder cancer. Additionally, Sesen Bio is developing VB6-845d, a systemically-administered product for various EpCAM-positive solid tumors. The company is also exploring combination therapies, including Vicinium with Durvalumab for high-risk non-muscle invasive bladder cancer and another combination for squamous cell carcinoma of the head and neck. Sesen Bio has partnered with Leiden University Medical Center to co-develop an imaging agent. Established in 2008 and previously known as Eleven Biotherapeutics, Sesen Bio has developed a proprietary platform that combines antibody fragments with cytotoxic proteins to create innovative therapies.

Novomer is a materials company based in Waltham, Massachusetts, founded in 2004. The company specializes in developing high-performance green plastics, polymers, and other chemicals using proprietary catalytic technology. This technology enables the cost-effective transformation of carbon dioxide and other renewable materials into various industrial products. By combining traditional chemical feedstocks with carbon dioxide or carbon monoxide, Novomer aims to create sustainable chemicals and materials for diverse applications, contributing to efforts in mitigating global warming and climate change.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Founded in 2005 through the merger of leading optical technology companies from Cambridge, Massachusetts, and Cambridge, UK, Polatis specializes in developing and providing optical switching solutions for modern fiber-based networks.

Carbon Design Systems, Inc. is a provider of virtual prototype solutions specifically designed for the development and validation of system-on-chip (SoC) designs. Founded in 2002 and based in Acton, Massachusetts, the company offers a range of products, including Carbon SoC Designer Plus, which facilitates the creation, execution, and analysis of virtual system platforms. Another key offering is Carbon Model Studio, which automates the generation and validation of hardware-accurate software models. Additionally, Carbon Performance Analysis Kits (CPAK) provide pre-built virtual reference platforms for critical performance elements such as processors and memory controllers. The company also supports performance optimization, system validation, and software execution, along with consulting, training, and integration services. Carbon Design Systems caters to systems, semiconductor, and intellectual property companies in sectors like wireless, networking, and consumer electronics, delivering essential tools for architectural analysis and pre-silicon validation.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

Avedro, Inc. is a commercial-stage ophthalmic pharmaceutical and medical device company headquartered in Waltham, Massachusetts. The company specializes in developing and commercializing innovative products for treating corneal disorders, primarily focusing on corneal ectatic conditions and refractive issues. Avedro's proprietary Corneal Remodeling Platform includes the KXL and Mosaic systems, which utilize ultraviolet A (UVA) light in conjunction with riboflavin drug formulations for corneal cross-linking. This technology is aimed at strengthening and reshaping the cornea through minimally invasive and non-invasive outpatient procedures. Avedro has also introduced the Keraflex refractive correction procedure, a non-invasive technique for flattening the cornea without tissue removal. While Avedro primarily serves ophthalmologists, hospitals, and ambulatory surgery centers in the United States, it also markets its products internationally through medical device distributors. The company, originally named ThermalVision, Inc., was incorporated in 2002 and rebranded as Avedro in 2005. As of November 2019, Avedro operates as a subsidiary of Glaukos Corporation.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Oasys Water, Inc. is a Boston-based company that specializes in forward osmosis technology aimed at addressing the global water crisis. Founded in 2008, the company has developed Engineered Osmosis, a proprietary platform that enhances the efficiency of desalination processes, making the treatment of saltwater more economical. Oasys Water's integrated systems focus on high recovery desalination, brine management, and zero liquid discharge solutions. By utilizing advanced resource recovery techniques, the company significantly lowers the cost of producing clean water and energy, enabling industries to optimize resource use while minimizing environmental impact. Oasys Water also maintains an office in Dubai to support its international operations.

Black Duck secures and manages open source software worldwide, eliminating open source security vulnerabilities and license compliance pain. With the rapid, widespread adoption of open-source software, Black Duck is a key component of Synopsys’ Software Integrity Platform, the most comprehensive solution for integrating security into the SDLC and software supply chain. Black Duck was established in 2002 and is based in Burlington, Massachusetts, United States.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

BG Medicine, Inc. is a life sciences company dedicated to the development and commercialization of diagnostic products aimed at assisting patients with heart failure and related disorders in the United States. The company offers the BGM Galectin-3 Test, an in vitro diagnostic device that quantifies galectin-3 levels in serum or plasma using an enzyme-linked immunosorbent assay on a microtiter plate platform. Additionally, BG Medicine provides the CardioSCORE Test, a multi-analyte biomarker-based blood test that evaluates the near-term risk of atherothrombotic cardiovascular events, including heart attacks and ischemic strokes. The company has established licensing and commercialization agreements with various healthcare organizations for automated versions of its galectin-3 test. Founded in 2000 and headquartered in Waltham, Massachusetts, BG Medicine was previously known as Beyond Genomics, Inc. before changing its name in 2004.

Agios Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapies in the field of cellular metabolism. It discovers and develops medicines for various indications, including hematologic malignancies, solid tumors, and rare genetic diseases.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Concert Pharmaceuticals is a clinical‑stage biopharmaceutical company headquartered in Lexington, Massachusetts, founded in 2006. The company develops small‑molecule therapies for autoimmune and central nervous system disorders using a precision deuterium chemistry platform that modifies drug molecules to improve efficacy, safety, and reduce development risk. Its pipeline includes CTP‑543, a Phase III candidate for alopecia areata; CTP‑692, a Phase II candidate for schizophrenia; and AVP‑786, a Phase III combination therapy for neurologic and psychiatric conditions such as agitation in Alzheimer’s disease. Concert collaborates with Avanir, Cipla Technologies, Processa, and Jazz Pharmaceuticals to advance its candidates. The firm focuses on orally administered agents and repurposed drugs for conditions including cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer’s agitation.

Carbon Design Systems, Inc. is a provider of virtual prototype solutions specifically designed for the development and validation of system-on-chip (SoC) designs. Founded in 2002 and based in Acton, Massachusetts, the company offers a range of products, including Carbon SoC Designer Plus, which facilitates the creation, execution, and analysis of virtual system platforms. Another key offering is Carbon Model Studio, which automates the generation and validation of hardware-accurate software models. Additionally, Carbon Performance Analysis Kits (CPAK) provide pre-built virtual reference platforms for critical performance elements such as processors and memory controllers. The company also supports performance optimization, system validation, and software execution, along with consulting, training, and integration services. Carbon Design Systems caters to systems, semiconductor, and intellectual property companies in sectors like wireless, networking, and consumer electronics, delivering essential tools for architectural analysis and pre-silicon validation.

Novomer is a materials company based in Waltham, Massachusetts, founded in 2004. The company specializes in developing high-performance green plastics, polymers, and other chemicals using proprietary catalytic technology. This technology enables the cost-effective transformation of carbon dioxide and other renewable materials into various industrial products. By combining traditional chemical feedstocks with carbon dioxide or carbon monoxide, Novomer aims to create sustainable chemicals and materials for diverse applications, contributing to efforts in mitigating global warming and climate change.

Interactive Supercomputing, Inc. was founded in 2004 and is headquartered in Waltham, Massachusetts. The company developed Star-P, an interactive parallel computing platform designed for automatic parallelization and execution of desktop simulation applications across various sectors, including biomedical, financial, and government laboratory research. Star-P enables users to perform scientific, engineering, or analytical computations on array or matrix-based data by leveraging parallel architectures such as multi-core workstations, multi-processor systems, and distributed memory clusters, as well as cloud-based environments. In addition to its software platform, Interactive Supercomputing provides customer support, professional services, application consulting, and training services. The company markets its products through authorized resellers both in the United States and internationally. In September 2009, Interactive Supercomputing was acquired by Microsoft Corporation.

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

Black Duck secures and manages open source software worldwide, eliminating open source security vulnerabilities and license compliance pain. With the rapid, widespread adoption of open-source software, Black Duck is a key component of Synopsys’ Software Integrity Platform, the most comprehensive solution for integrating security into the SDLC and software supply chain. Black Duck was established in 2002 and is based in Burlington, Massachusetts, United States.

Everyday Solutions, Inc. specializes in GPS-based vehicle tracking solutions tailored for the student transportation market in the United States and Canada. The company delivers real-time tracking services that ensure route compliance, driver safety, student attendance monitoring, automatic notifications for parents, and comprehensive management reporting. Founded in 2000 as Everyday Wireless, Inc., it rebranded to Everyday Solutions, Inc. in July 2008. Headquartered in Concord, Massachusetts, the company has established strategic partnerships with various organizations, enhancing its service offerings within the pupil transportation sector.

Ensemble Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering and developing innovative small molecule therapies for cancer and other serious diseases. The company's pipeline primarily emphasizes immuno-oncology programs, including targets like Indoleamine 2,3-dioxygenase 1 (IDO-1) and Ubiquitin-specific protease 9x. Additionally, Ensemble Therapeutics explores inhibitors of apoptosis proteins such as XIAP and cIAP, as well as Cyclophilins, which play roles in protein folding and cancer progression. The company aims to address drug targets that are typically considered inaccessible with conventional small molecule drugs, offering patients new treatment options.

Concert Pharmaceuticals is a clinical‑stage biopharmaceutical company headquartered in Lexington, Massachusetts, founded in 2006. The company develops small‑molecule therapies for autoimmune and central nervous system disorders using a precision deuterium chemistry platform that modifies drug molecules to improve efficacy, safety, and reduce development risk. Its pipeline includes CTP‑543, a Phase III candidate for alopecia areata; CTP‑692, a Phase II candidate for schizophrenia; and AVP‑786, a Phase III combination therapy for neurologic and psychiatric conditions such as agitation in Alzheimer’s disease. Concert collaborates with Avanir, Cipla Technologies, Processa, and Jazz Pharmaceuticals to advance its candidates. The firm focuses on orally administered agents and repurposed drugs for conditions including cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer’s agitation.

Carbon Design Systems, Inc. is a provider of virtual prototype solutions specifically designed for the development and validation of system-on-chip (SoC) designs. Founded in 2002 and based in Acton, Massachusetts, the company offers a range of products, including Carbon SoC Designer Plus, which facilitates the creation, execution, and analysis of virtual system platforms. Another key offering is Carbon Model Studio, which automates the generation and validation of hardware-accurate software models. Additionally, Carbon Performance Analysis Kits (CPAK) provide pre-built virtual reference platforms for critical performance elements such as processors and memory controllers. The company also supports performance optimization, system validation, and software execution, along with consulting, training, and integration services. Carbon Design Systems caters to systems, semiconductor, and intellectual property companies in sectors like wireless, networking, and consumer electronics, delivering essential tools for architectural analysis and pre-silicon validation.

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

Interactive Supercomputing, Inc. was founded in 2004 and is headquartered in Waltham, Massachusetts. The company developed Star-P, an interactive parallel computing platform designed for automatic parallelization and execution of desktop simulation applications across various sectors, including biomedical, financial, and government laboratory research. Star-P enables users to perform scientific, engineering, or analytical computations on array or matrix-based data by leveraging parallel architectures such as multi-core workstations, multi-processor systems, and distributed memory clusters, as well as cloud-based environments. In addition to its software platform, Interactive Supercomputing provides customer support, professional services, application consulting, and training services. The company markets its products through authorized resellers both in the United States and internationally. In September 2009, Interactive Supercomputing was acquired by Microsoft Corporation.

Calpurnia Corporation provides intelligent video analysis solutions for the retail industry. It offers Video Investigator software for loss prevention and store intelligence solutions. The company's software protects people and assets in support of loss prevention, customer safety, and compliance policy efforts. Calpurnia's professional services offer a range of consulting, training, and implementation services. The company was founded in 2002 as IntelliVid Corporation and changed its name to Calpurnia Corporation in July 2008. The company is headquartered in Cambridge, Massachusetts. As of July 16, 2008, Calpurnia Corporation operates as a subsidiary of Tyco International Ltd.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.